News AbbVie bullish on Humira and near-term pipeline Sales of Humira could peak above $18 billion - CEO
News Amjevita, first Humira biosimilar approved – but no launch y... Amgen's biosimilar is ready to go, but AbbVie believes it can delay until 2022
News AbbVie waits on data from Humira successor Ablynx's vobarilizumab seen as key should Humira sales fall.
News Biogen eyeing big-selling biosimilars as MS drug fails Gamble on opicinumab looks unlikely to pay off.
News Amgen biosimilar stands up against Humira Amgen's biosimilar candidate ABP 501 has shown comparable results in phase III, measured against AbbVie's blockbuster Humira (adalimumab), for patients with moderate-to-severe plaque psoria
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
